McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about what drove him to CRG after a long tenure with Abbott.
Tag: Abbott
Late-Breaking Data Show Breadth of Abbott’s Minimally Invasive Structural Heart Technologies
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott’s structural heart devices to repair or replace heart valves and close openings in the heart New data reinforce the safety and effectiveness of MitraClip™ for treating mitral regurgitation Results also demonstrate the benefits of Abbott’s TriClip™ for tricuspid regurgitation, […]
Investor Insights: Sabir Rassiwalla – What Makes CRG Different From Other Healthcare Investors? (Part 2)
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about how CRG is different from healthcare investment partners in the market.
THREE-YEAR DATA ON WORLD’S SMALLEST HEART DEVICE SHOW BENEFITS OF FIXING HOLES IN NEWBORN HEARTS WITHOUT SURGERY
Results reinforce that Amplatzer Piccolo™ Occluder is safe and effective for closing an opening in the heart known as a “patent ductus arteriosus” (PDA) in newborns Study found low adverse event rates following a Piccolo procedure, showing additional benefit of the device that can help babies avoid riskier surgery A […]
ABBOTT ANNOUNCES EUROPEAN LAUNCH OF AMPLATZER™ TALISMAN™ SYSTEM TO CLOSE HOLE IN HEART FOR PEOPLE AT RISK OF RECURRENT STROKE
– Abbott’s Talisman system seals an opening in the heart known as a “patent foramen ovale” (PFO) to prevent blood clots from passing from the right to the left side of the heart and on to the brain, where they can cause a stroke – The Talisman system builds on […]
New Data Show Abbott’s HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who don’t receive either a heart pump or heart transplant is […]
Investor Insights: Sabir Rassiwalla – How Has MedTech’s Changing Landscape Brought You to CRG? (Part 1)
McDermott + Bull Partner Ken Dropiewski talks with CRG Director Sabir Rassiwalla about what drove him to CRG after a long tenure with Abbott.
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
Sales growth of 10.1 percent; organic sales growth of 14.3 percent GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent Global COVID-19 testing-related sales of $2.3 billion in the second quarter Continues to strengthen portfolio with new product approvals ABBOTT PARK, Ill., July 20, 2022 /PRNewswire/ — Abbott (NYSE: ABT) […]
LATE-BREAKING DATA REINFORCE BROAD RANGE OF PATIENTS BENEFIT FROM ABBOTT’S MITRAL AND TRICUSPID HEART VALVE DEVICES
– New results demonstrate MitraClip™ transcatheter edge-to-edge repair (TEER) is effective at treating leaky valves in people with secondary mitral regurgitation (MR) – Data from the first report on patients with a pacemaker lead across the tricuspid valve show TriClip™ and TriClip G4 TEER systems significantly reduce tricuspid regurgitation (TR) […]
New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
Data presented at EuroPCR 2022 reinforce the impact of Abbott’s minimally invasive heart devices on patient outcomes and quality of life Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system […]
Recent
SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified Lesions
Late-Breaking Clinical Trial Results Announced at VIVA 2025
Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial
Popular
- No commented posts yet